Metastatic NSCLC patients in the real world in Finland
DOI:
https://doi.org/10.2340/1651-226X.2025.44254Keywords:
Carcinoma, non-small-cell lung, retrospective studies, neoplasm metastasis, immune checkpoint inhibitors, treatment outcomeAbstract
Background: Significant progress has been made in the management of metastatic NSCLC (mNSCLC). Our study investigated characteristics, treatment patterns, and outcomes in this patient population and subgroups based on histology and PD-L1 status.
Methods: We conducted a retrospective analysis of electronic health records of patients with mNSCLC 1/2019-8/2023 at HUS, Helsinki University Hospital, Finland. Patient characteristics, treatment, and outcomes were analyzed.
Results: We identified 646 patients with mNSCLC, including those metastatic at diagnosis and whose cancer later progressed to metastatic, who received systemic therapy. Median age was 70 years (interquartile range [IQR]: 62–75). Squamous cell carcinoma (SqC) presented 19% of patients, adenocarcinoma 68%, and other non-SqC 13%. Amongst the non-SqC patients 53% were female, whereas only 32% of SqC patients were female. Treatment evolved considerably, with increased use of immuno-oncology (IO) and tyrosine kinase inhibitor (TKI) therapies. Median overall survival was 8 months (confidence interval [CI] 95%: 6–9) for those treated with chemotherapy alone, 12 months (CI 95%: 7–18) for those treated with IO therapy, 14 months (CI 95%: 11–15) for those treated with IO + chemotherapy, and 24 months (CI 95%: 16–38) for those treated with TKIs.
Interpretation: Our study reports real-world management of patients with mNSCLC and evolving treatment patterns in clinical practice from the first years of IO treatment availability. As we continue to monitor more recent data, the proportion receiving chemotherapy alone is anticipated to continue decreasing. It is crucial to assess current outcomes in NSCLC to target resources correctly and improve prognosis.
Downloads
References
Malila N, Pitkäniemi J, Hermiö E, Johansson S, Seppä K, Toikkanen S. Keuhkosyöpä Suomessa (Lung cancer in Finland). Helsinki: Cancer Society of Finland; 2024. [cited August 8, 2025]. Available from: https://syoparekisteri.fi/assets/files/2024/12/Keuhkosyopa_Suomessa.pdf
Larønningen S, Arvidsson G, Bray F, Dahl-Olsen E, Engholm G, Ervik M, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic Countries, Version 9.5 (19.06.2025). [Internet]. Association of the Nordic Cancer Registries. Cancer Registry of Norway. [cited 2025 Oct 9]. Available from: https://nordcan.iarc.fr/
Dansk Lunge Cancer Gruppe / Register. Dansk Lunge Cancer Register Årsrapport 2022. 2023 Jun. Report No.: 2022. [cited August 22, 2025]. Available from: https://www.lungecancer.dk/wp-content/uploads/2023/06/%C3%85rsrapport-2022-DLCR-offentlig.pdf
Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intra-tumor heterogeneity in localized lung adenocarcinomas delineated by multi-region sequencing. Science. 2014 Oct 10;346(6206):256–9.
https://doi.org/10.1126/science.1256930 DOI: https://doi.org/10.1126/science.1256930
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018 Jan;553(7689):446–54.
https://doi.org/10.1038/nature25183 DOI: https://doi.org/10.1038/nature25183
Loponen H, Paajanen J, Vihervaara V, Ylä-Viteli S, Tamminen K, Torvinen S, et al. Treatment patterns and outcomes in a cohort of Finnish NSCLC patients with ALK rearrangement reflect rapid evolution in treatment practices. Int J Clin Exp Med Sci. 2021 Dec 24;7(6):200.
Leskelä RL, Peltonen E, Haavisto I, Herse F, Korhonen S, Nolvi K, et al. Trends in treatment of non-small cell lung cancer in Finland 2014–2019. Acta Oncol. 2022 May 4;61(5):641–8.
https://doi.org/10.1080/0284186X.2022.2042474 DOI: https://doi.org/10.1080/0284186X.2022.2042474
Anttalainen A, Pietarinen P, Tuominen S, Mattila R, Mutka A, Knuuttila A. Real-world evidence study of patients with KRAS-mutated NSCLC in Finland. Curr Oncol. 2024 May 11;31(5):2700–12.
https://doi.org/10.3390/curroncol31050205 DOI: https://doi.org/10.3390/curroncol31050205
Paakkola NM, Jekunen A, Sihvo E, Johansson M, Andersén H. Area-based disparities in non-small-cell lung cancer survival. Acta Oncol. 2024 Apr 9;63:27507.
https://doi.org/10.2340/1651-226X.2024.27507 DOI: https://doi.org/10.2340/1651-226X.2024.27507
Manninen O, Puuniemi L, Iivanainen S, Arffman M, Kaarteenaho R, Koivunen JP. Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study. Acta Oncol. 2023 Dec 2;62(12):1854–61.
https://doi.org/10.1080/0284186X.2023.2274481 DOI: https://doi.org/10.1080/0284186X.2023.2274481
Kuusisalo S, Tikkanen A, Lappi-Blanco E, Väisänen T, Knuuttila A, Tiainen S, et al. The prognostic and predictive roles of plasma C-reactive protein and PD-L1 in non-small cell lung cancer. Cancer Med. 2023 Aug;12(15):16087–97.
https://doi.org/10.1002/cam4.6262 DOI: https://doi.org/10.1002/cam4.6262
Manninen O, Iivanainen S, Arffman M, Koivunen JP. Non-small cell lung cancer treated with epidermal growth factor receptor inhibitors: the effect of concurrent medications on patient outcomes. Oncology. 2025;103(10):907–920.
https://doi.org/10.1159/000543163 DOI: https://doi.org/10.1159/000543163
Kim K, Sweeting M, Wilking N, Jönsson LM. Cost of treatment of metastatic non-small lung cancer in Sweden, 2011–2023. Acta Oncol. 2025 Oct 26;64:1473–81.
https://doi.org/10.2340/1651-226X.2025.44650 DOI: https://doi.org/10.2340/1651-226X.2025.44650
Finnish Cancer Center FICAN, Finnish Lung Cancer Group. Finnish national treatment guideline for lung cancer [Keuhkosyövän kansallinen hoitosuositus]. Helsinki: Finnish Cancer Center FICAN, Finnish Lung Cancer Group; 2023.
Simeone JC, Nordstrom BL, Patel K, Klein AB. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting. Future Oncol. 2019 Oct 31;15(30):3491–502.
https://doi.org/10.2217/fon-2019-0348 DOI: https://doi.org/10.2217/fon-2019-0348
Lester J, Escriu C, Khan S, Hudson E, Mansy T, Conn A, et al. 1379P Real-world (RW) clinical outcomes of patients with metastatic non-small cell lung cancer (mNSCLC) in the United Kingdom. Ann Oncol. 2020 Sep;31:S878–9.
https://doi.org/10.1016/j.annonc.2020.08.1693 DOI: https://doi.org/10.1016/j.annonc.2020.08.1693
Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY, et al. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol. 2019 Jun;145(6):1613–23.
https://doi.org/10.1007/s00432-019-02899-y DOI: https://doi.org/10.1007/s00432-019-02899-y
Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023 Apr 10;41(11):1992–8.
https://doi.org/10.1200/JCO.22.01989 DOI: https://doi.org/10.1200/JCO.22.01989
Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, et al. Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol. 2023 Apr 10;41(11):1999–2006.
https://doi.org/10.1200/JCO.22.01990 DOI: https://doi.org/10.1200/JCO.22.01990
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41–50.
https://doi.org/10.1056/NEJMoa1913662 DOI: https://doi.org/10.1056/NEJMoa1913662
Wagenius G, Vikström A, Berglund A, Salomonsson S, Bencina G, Hu X, et al. Long-term real-world outcomes of first-line immunotherapy in non-small cell lung cancer – a population-based cohort study in Sweden. Acta Oncol. 2025 Mar 17;64:415–22.
https://doi.org/10.2340/1651-226X.2025.42746 DOI: https://doi.org/10.2340/1651-226X.2025.42746
Børø S, Thoresen S, Helland Å. Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010–2020 – a population-based registry study from Norway. Front Oncol. 2022;12:1017902.
https://doi.org/10.3389/fonc.2022.1017902 DOI: https://doi.org/10.3389/fonc.2022.1017902
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Heikki Ekroos, Olivia Hölsä, Anna Kreutzman, Lila Nikkola, Johanna Vikkula, Riikka Mattila, Aija Knuuttila
This work is licensed under a Creative Commons Attribution 4.0 International License.
